Vectibix(panitumumab)
Vectibix (panitumumab) is an antibody pharmaceutical. Panitumumab was first approved as Vectibix on 2006-09-27. It is used to treat colorectal neoplasms in the USA. It has been approved in Europe to treat colorectal neoplasms. The pharmaceutical is active against epidermal growth factor receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Vectibix
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Panitumumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Vectibix | panitumumab | Amgen | N-125147 RX | 2006-09-27 | 2 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vectibix | Biologic Licensing Application | 2017-06-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colorectal neoplasms | — | D015179 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9303 | Injection, panitumumab, 10 mg |
Clinical
Clinical Trials
226 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 15 | 79 | 16 | — | 6 | 106 | ||
| Colonic neoplasms | D003110 | C18 | 5 | 13 | 1 | — | — | 15 | |
| Head and neck neoplasms | D006258 | 3 | 7 | 2 | — | — | 12 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 6 | 1 | — | — | 7 | |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | 3 | 12 | — | — | — | 13 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 7 | — | — | — | 10 |
| Squamous cell carcinoma of head and neck | D000077195 | 3 | 7 | — | — | — | 10 | ||
| Non-small-cell lung carcinoma | D002289 | 4 | 7 | — | — | — | 10 | ||
| Adenocarcinoma | D000230 | 1 | 8 | — | — | — | 8 | ||
| Esophageal neoplasms | D004938 | C15 | 3 | 5 | — | — | — | 7 | |
| Lung neoplasms | D008175 | C34.90 | 4 | 5 | — | — | — | 7 | |
| Squamous cell neoplasms | D018307 | 1 | 6 | — | — | — | 7 | ||
| Cholangiocarcinoma | D018281 | C22.1 | — | 6 | — | — | — | 6 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 6 | — | — | — | 6 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PANITUMUMAB |
| INN | panitumumab |
| Description | Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal ABX-EGF heavy chain), disulfide with human monoclonal ABX-EGF light chain, dimer |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5SX5:J,H|Panitumumab Fab Heavy Chain
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQF
SLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC
>5SX5:K,L|Panitumumab Fab Light Chain
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQP
EDIATYFCQHFDHLPLAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 5SX4, 5SX5 |
| CAS-ID | 339177-26-3 |
| RxCUI | 263034 |
| ChEMBL ID | CHEMBL1201827 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01269 |
| UNII ID | 6A901E312A (ChemIDplus, GSRS) |
Target
Agency Approved
EGFR
EGFR
Organism
Homo sapiens
Gene name
EGFR
Gene synonyms
ERBB, ERBB1, HER1
NCBI Gene ID
Protein name
epidermal growth factor receptor
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EGFR vIII, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Uniprot ID
Mouse ortholog
Egfr (13649)
epidermal growth factor receptor (Q01279)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vectibix - Amgen
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,224 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vectibix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,004 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more